This summary was created by AI, based on 1 opinions in the last 12 months.
Experts are optimistic about the positive results of Alnylam Pharmaceuticals' heart disease drug, which has had a positive impact on the company's shares. The potential for M&A in this space and declining interest rates are also seen as positive factors. However, there is a cautious wait-and-see approach regarding the future outcome. The experts believe the drug will perform well this year despite potential challenges related to drug pricing in an election year.
Alnylam Pharmaceuticals is a American stock, trading under the symbol ALNY-Q on the NASDAQ (ALNY). It is usually referred to as NASDAQ:ALNY or ALNY-Q
In the last year, 1 stock analyst published opinions about ALNY-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Alnylam Pharmaceuticals.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Alnylam Pharmaceuticals published on Stockchase.
On 2024-12-13, Alnylam Pharmaceuticals (ALNY-Q) stock closed at a price of $245.44.
Positive results of their heart disease drug lifted shares today. M&A in this space and declining interest rates have been positive. We'll see what happens here. Drug pricing is always an issue in election years, but he thinks this will do well this year.